Viela Bio (Viela Bio) Inventory-to-Revenue : 0.05 (As of Dec. 2020)

View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Viela Bio's Average Total Inventories for the quarter that ended in Dec. 2020 was $0.44 Mil. Viela Bio's Revenue for the three months ended in Dec. 2020 was $9.34 Mil. Viela Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2020 was 0.05.

Viela Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2020 declined from Sep. 2020 (0.19) to Sep. 2020 (0.05)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Viela Bio's Days Inventory for the three months ended in Dec. 2020 was 28.75.

Inventory Turnover measures how fast the company turns over its inventory within a year. Viela Bio's Inventory Turnover for the quarter that ended in Dec. 2020 was 3.17.

Viela Bio Inventory-to-Revenue Historical Data

The historical data trend for Viela Bio's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Inventory-to-Revenue Chart

Viela Bio Annual Data

Trend

Dec18

Dec19

Dec20

Inventory-to-Revenue

Viela Bio Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Inventory-to-Revenue	Get a 7-Day Free Trial					-	-	-	0.19	0.05

Competitive Comparison of Viela Bio's Inventory-to-Revenue

For the Biotechnology subindustry, Viela Bio's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viela Bio's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viela Bio's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Viela Bio's Inventory-to-Revenue falls into.

Viela Bio Inventory-to-Revenue Calculation

Viela Bio's Inventory-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

	Inventory-to-Revenue (A: Dec. 2020 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2019 )	+	Total Inventories (A: Dec. 2020 ))	/	count )	/	Revenue (A: Dec. 2020 )
=	( (0	+	0)	/	1 )	/	11.652
=	0					/	11.652
=	0.00

Viela Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2020 is calculated as

	Inventory-to-Revenue (Q: Dec. 2020 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2020 )	+	Total Inventories (Q: Dec. 2020 ))	/	count )	/	Revenue (Q: Dec. 2020 )
=	( (0.438	+	0)	/	1 )	/	9.336
=	0.438					/	9.336
=	0.05

Viela Bio (NAS:VIE) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Viela Bio's Days Inventory for the three months ended in Dec. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2020 )	/	Cost of Goods Sold (Q: Dec. 2020 )	*	Days in Period
	=	0.438	/	1.39	*	365 / 4
	=	28.75

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Viela Bio's Inventory Turnover for the quarter that ended in Dec. 2020 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2020 )	/	Average Total Inventories (Q: Dec. 2020 )
	=	1.39	/	0.438
	=	3.17

Viela Bio Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Viela Bio's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Viela Bio (Viela Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878

Website

https://www.vielabio.com

Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.

Executives

Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu	director	10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd	10 percent owner	SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund	10 percent owner	CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao	director, officer: Chief Executive Officer	10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz	officer: VP, Head of Commercial	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878